Modulation of the Kynurenine Pathway in Search for New Neuroprotective Agents.Synthesis and Preliminary Evaluation of (m-Nitrobenzoyl)alanine, a Potent Inhibitor of Kynurenine-3-hydroxylase
Open accessThe DOI matches its Crossref record.
Abstract
The synthesis of (o-nitrobenzoyl)-, (m-nitrobenzoyl)-, and (p-nitrobenzoyl)alanine (o-, m-, and p-NBA), three new kynurenine analogues, and their evaluation as inhibitors of kynureninase and kynurenine-3-hydroxylase are reported. The most potent of these compounds, m-NBA, has an IC50 of 0.9 +/- 0.1 microM as an inhibitor of kynurenine-3-hydroxylase and of 100 +/- 12 microM as an inhibitor of kynureninase. When administered to rats, m-NBA significantly increases the concentration of kynurenine and kynurenic acid in the brain as well as in blood and in the liver. m-NBA has also been shown to increase the concentration of kynurenic acid in hippocampal extracellular fluid. This increase is associated with sedative and anticonvulsant activities, thus confirming the possibility of antagonizing L-glutamate-mediated effects by modulating the kynurenine pathway of L-tryptophan metabolism.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Hilmas, C., Pereira, E. F. R., Alkondon, M., Rassoulpour, A., Schwarcz, R., & Albuquerque, E. X. (2001) · The Journal of Neuroscience · doi:10.1523/jneurosci.21-19-07463.2001 · Cited by 859
Maes, M., Leonard, B. E., Myint, A. M., Kubera, M., & Verkerk, R. (2011) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2010.12.017 · Cited by 700
Kynurenines in the CNS: recent advances and new questions
Vécsei, L., Szalárdy, L., Fülöp, F., & Toldi, J. (2013) · Nature Reviews Drug Discovery · doi:10.1038/nrd3793 · Cited by 641
Kynurenine Pathway Metabolites in Humans: Disease and Healthy States
Chen, Y., & Guillemin, G. J. (2009) · International Journal of Tryptophan Research · doi:10.4137/ijtr.s2097 · Cited by 628
Increased cortical kynurenate content in schizophrenia
Schwarcz, R., Rassoulpour, A., Wu, H.-Q., Medoff, D., Tamminga, C. A., & Roberts, R. C. (2001) · Biological Psychiatry · doi:10.1016/s0006-3223(01)01078-2 · Cited by 590
Manipulation of Brain Kynurenines: Glial Targets, Neuronal Effects, and Clinical Opportunities
Schwarcz, R., & Pellicciari, R. (2002) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.102.034439 · Cited by 556
Self-citationTryptophan metabolism and brain function: focus on kynurenine and other indole metabolites
Moroni, F. (1999) · European Journal of Pharmacology · doi:10.1016/s0014-2999(99)00196-x · Cited by 346
Self-citationKynurenines in the CNS: from endogenous obscurity to therapeutic importance
Stone, T. W. (2001) · Progress in Neurobiology · doi:10.1016/s0301-0082(00)00032-0 · Cited by 306
The kynurenine pathway as a therapeutic target in cognitive and neurodegenerative disorders
Stone, T. W., & Darlington, L. G. (2013) · British Journal of Pharmacology · doi:10.1111/bph.12230 · Cited by 271
Röver, S., Cesura, A. M., Huguenin, P., Kettler, R., & Szente, A. (1997) · Journal of Medicinal Chemistry · doi:10.1021/jm970467t · Cited by 211
Stone, T. W. (2000) · Trends in Pharmacological Sciences · doi:10.1016/s0165-6147(00)01451-6 · Cited by 211
Kynurenic acid in neurodegenerative disorders-unique neuroprotection or double-edged sword?
Ostapiuk, A., & Urbanska, E. M. (2022) · CNS Neuroscience & Therapeutics · doi:10.1111/cns.13768 · Cited by 142
Kynurenic acid antagonists and kynurenine pathway inhibitors
Stone, T. W. (2001) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.10.4.633 · Cited by 79
Metadata
- Authors
- Pellicciari, R., Natalini, B., Costantino, G., Mahmoud, M. R., Mattoli, L., Sadeghpour, B. M., Moroni, F., Chiarugi, A., & Carpenedo, R.
- Venue
- Journal of Medicinal Chemistry
- Publisher
- American Chemical Society (ACS)
- Published
- 1994-03
- Volume
- 37
- Issue
- 5
- Pages
- 647-655
- ISSN
- 0022-2623 (ISSN-L)
- 1520-4804
- OpenAlex
- W2054921486
- Cited by
- 136
- References
- 0
- FWCI
- 3.28
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.